Please login to the form below
New Accounts: June - PR and medical education
The following tables list new pharmaceutical account wins notified to us by the winning agencies for the period March 2006 to May 2006 inclusive
The following tables list new pharmaceutical account wins notified to us by the winning
agencies for the period March 2006 to May 2006 inclusive. Please note that inclusion in this table does not necessarily indicate exclusivity and other agencies may also be involved with some of the products listed in other ways, or in domestic, overseas or international markets.
To submit an entry for New Accounts, email new_accounts@pmlive.com
|
|
|
|
|
|
The Alliance for Better Bone (P&G; S-A) |
Actonel |
Osteoporosis |
Ketchum |
|
ABPI |
The Involved Patient Initiative |
N/A |
Shire Health London |
|
Altana Pharma |
Pantoprazole |
Gastrointestinal |
Shire Health London |
|
Apitope Technology |
Phase Ib/IIa therapeutic biological vaccine |
MS |
Healthcare Solutions |
|
AstraZeneca |
Crestor |
Cardiovascular |
Zaicom MMC |
|
GlaxoSmithKline |
HPV vaccine |
Gynaecology/oncology |
Succinct Communications |
|
GlaxoSmithKline |
Telzir |
HIV |
90TEN Healthcare |
|
GrÈnenthal International |
Transtec - publications planning |
Pain |
Zaicom MMC |
|
Kimberly-Clark |
InteguSeal |
Antimicrobial surgical skin preparation |
De Facto Medica |
|
Link Pharmaceuticals |
Gliadel implant |
Oncology |
Spink Consumer Relations |
|
Merck SantÈ |
Glucovance |
Type II diabetes |
De Facto Medica |
|
NICE |
At Ri-SK? awareness campaign |
Solar keratosis |
hsdcommunications |
|
NICE |
Quick Reference Guides |
N/A |
90TEN Healthcare |
|
Pfizer |
Oncology portfolio |
Managed entry |
Succinct Communications |
|
Plethora/Timm |
Osbon ErecAid |
Male sexual dysfunction |
De Facto Medica |
|
ProStrakan |
Rapinyl |
Breakthrough pain |
Litmus/CCA |
|
Recordati |
Zanidip |
Cardiology |
LeapFrog Medical Communications |
|
Roche Pharmaceuticals |
Fuzeon/Invirase |
HIV |
Aurora |
|
Schering-Plough |
Nasonex |
Respiratory disease |
LeapFrog Medical Communications |
|
Servier |
Various |
Cardiology |
Zaicom MMC |
|
Speedel |
SPP301 |
Hypertension |
De Facto Medica |
|
UCB |
Professional development programme |
ADHD |
Huntsworth Health Avenue |
|
Wyeth Consumer Health |
Anadin |
Analgesics |
Spink Consumer Relations |
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- EU “still interested” in Valneva COVID vaccine despite UK snub
- Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%
- US demand for COVID-19 antibody treatments rising fast
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- COVID-19 Pfizer/BioNTech booster approved by FDA and CDC
- AstraZeneca invests in RNA tech platform
- Market shaping demands behaviour change
- Healthcare Access and Payment Reform in the US
- Advancing Drug Discovery with Structured and Intelligent Data
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
- David Hunt launches independent agency The Considered
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Lilly’s tirzepatide shows superiority over Novo’s semaglutide in type 2 diabetes trial
- WHO to test three more potential COVID-19 treatments
- Langland promotes Jake Davis to managing partner
- Patient diversity in clinical trials needs to be centre stage
PMHub
Dice Medical Communications
Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
